These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15951531)

  • 21. Phosphatidylcholine as a constituent in the colonic mucosal barrier--physiological and clinical relevance.
    Ehehalt R; Braun A; Karner M; Füllekrug J; Stremmel W
    Biochim Biophys Acta; 2010 Sep; 1801(9):983-93. PubMed ID: 20595010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of TNFalpha in ulcerative colitis.
    Sands BE; Kaplan GG
    J Clin Pharmacol; 2007 Aug; 47(8):930-41. PubMed ID: 17567930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal protection by phosphatidylcholine.
    Stremmel W; Ehehalt R; Staffer S; Stoffels S; Mohr A; Karner M; Braun A
    Dig Dis; 2012; 30 Suppl 3():85-91. PubMed ID: 23295697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update in the treatment of paediatric ulcerative colitis.
    Greifer MK; Markowitz JF
    Expert Opin Pharmacother; 2006 Oct; 7(14):1907-18. PubMed ID: 17020417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current management of severe ulcerative colitis.
    Caprilli R; Viscido A; Latella G
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):92-101. PubMed ID: 17268544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
    Lawrance IC
    Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
    Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
    Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis?
    Stremmel W; Hanemann A; Ehehalt R; Karner M; Braun A
    Dig Dis; 2010; 28(3):490-6. PubMed ID: 20926877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab for the treatment of ulcerative colitis.
    Rietdijk ST; D'Haens GR
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of steroid-naive ulcerative colitis.
    Bossa F; Colombo E; Andriulli A; Annese V
    Expert Opin Pharmacother; 2009 Jun; 10(9):1449-60. PubMed ID: 19445560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
    Merga Y; Campbell BJ; Rhodes JM
    Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.